Bufexamac
| File:Bufexamac.png | |
| Systematic (IUPAC) name | |
|---|---|
|
2-(4-butoxyphenyl)-N-hydroxyacetamide | |
| Clinical data | |
| Routes of administration | Topical, rectal |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 2438-72-4 |
| ATC code | M01AB17 (WHO) M02AA09 |
| PubChem | CID 2466 |
| Chemical data | |
| Formula | C12H17NO3 |
| Molar mass | 223.268 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Bufexamac is a drug used as an anti-inflamatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac.
Indications
Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns[citation needed], and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.[1]
Pharmacology
Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it an non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.[2]
Side-effects
Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.[3] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.[4]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German) (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-98-46-3. Text "volume2" ignored (help)
- ↑ Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3540671749.
- ↑ "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt (in German) (47). 2000.
- ↑ "European Medicines Agency recommends revocation of marketing authorisations for bufexamac" (PDF). European Medicines Agency. 22-04-2010. Check date values in:
|date=(help)
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- All articles with unsourced statements
- Articles with unsourced statements from May 2010
- Articles with invalid date parameter in template
- 2Fix
- Anti-inflammatory agents
- Hydroxamic acids
- Phenol ethers
- Pages with citations using unnamed parameters
- CS1 maint: Multiple names: editors list
- CS1 maint: Unrecognized language
- CS1 errors: dates
